Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Development of culture conditions for the differentiation of hES cells into hepatocytes (LIV-ES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,Israel,Spain,France,Finland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2012-03-31
Duration (months): 42.0
Total project cost (EUR): 4231982.0
EU funding (EUR): 2999879.0
Participants: 7
Project status: CLOSED

The liver is associated with many types of diseases which can only be treated by Orthotopic liver transplants. However, shortage of organ donors represents a major limitation for wide-application of this therapy. Additionally, expansion of fully-functional hepatocytes in vitro remains an important challenge for the drug discovery industry. Human Embryonic Stem cells (hESCs) offer a promising new solution to these problems. hESCs are able to grow indefinitely in vitro while maintaining their capacity to differentiate to all types of cells. Here we propose to develop standardized, animal-free culture conditions to promote the differentiation and expansion of fully-functional hepatocytes from hESCs using four complementary Workpackages (WPs): Development of novel tools: WP1 will develop 3-D growth matrices, lentivirus-based reporter systems, liver-specific endothelial cells and a miRNA platform to facilitate the sequential process of establishing standardized, animal-free conditions to produce ES-derived hepatocytes. Generation of Anterior Definitive Endoderm multipotent stem cells: WP2 will define culture conditions to drive differentiation of hESCs to ADE cells, the earliest progenitors of liver cells during mammalian development. Proof-of-principle of conditions will be validated using the various hESC lines available from partners. Differentiation and expansion of hepatic progenitors from multipotent ADE cells using defined conditions: WP3 will be devoted to the generation of hepatic progenitors from ADE cells. Function will be validated in vitro and in vivo using human foetal hepatic progenitors and HepaRG human hepatoma cells as positive controls. Generation of mature hepatocytes from ES-derived hepatic progenitors: WP4 will generate functional hepatocyte lines suitable for drug testing and future preclinical evaluation. Results of the LIV-ES project will provide new insights into stem cell biology and establish a rationale basis for cell-based therapies.

Keywords: human embryonic stem cells,animal-free defined culture conditions,hepatocyte differentiation,toxicology,cell therapy,liver diseases
Pricing Policies and Control of Tobacco in Europe (PPACTE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Ireland,United Kingdom,France,Italy,Spain,France,Finland,United States
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2012-04-30
Duration (months): 39.0
Total project cost (EUR): 3749399.4
EU funding (EUR): 2991656.0
Participants: 8
Project status: CLOSED

Price is the single most important intervention in tobacco control (TC). To protect the health of its citizens the EU now has a major role in regulating tobacco fiscal policy (FP) through a number of EU directives. The aims of these directives initially were to ensure the proper functioning of the internal market. The directives aided harmonization in EU Member States (MS) but now with EU enlargement price differentials have increased problems for the market and health protection. Price elasticity of tobacco is estimated using econometric analysis of demand but is limited in MS by availability of relevant data. The interaction of FP with other TC policies is poorly defined. The effects of price on smuggling and the tobacco industry response to price changes are complex. Gradually tools are evolving to look at some of these problems. The World Bank has produced a toolkit for economic analysis of tobacco demand with clear guidance on methodology. SimSmoke has allowed the analysis of various TC components to be investigated. This project allows us to perform an econometric analysis at EU level with routinely collected aggregated time series data examining differences in EU MS and the influence of EU border countries. A new cross sectional survey will provide standardised data for EU MS We will examine the effect of the rate of price changes using historical data comparing steep rapid changes e.g. in France with gradual changes in e.g. UK and Ireland. Using SimSmoke we will examine the effects of the interaction of price with: Smoking Cessation Services, Smuggling in high, (Finland, Ireland, UK) and low, (Baltic, Romania) price countries, Smoke free laws (Ireland, Scotland and Italy), Advertising and warnings (Belgium, UK) and predict the effects on other MS. Outputs: Recommendations for policymakers at EU and MS levels with SimSmoke models and a Fiscal Policy Handbook for MS to strengthen tobacco control policies and lead to an equitable EU tobacco market

Keywords: fiscal policy,econometric analysis,tobacco control,cross sectional survey,simsmoke
PRe-clinicAl studies of a PSA-based human vaccine candidate targeting visceral, cutaneOus and mucocutaneous Leishmaniasis and Development of the associated procedures for further clinical trials (RAPSODI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,France,Spain,India,Peru,Tunisia,France,France
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 4004911.3
EU funding (EUR): 2737149.0
Participants: 9
Project status: CLOSED

The global aim of RAPSODI is : · to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). · to establish all the associated procedures required for the subsequent clinical trials, such as the selection of the appropriate patients and assessment of vaccine efficiency. For that purpose, an international consortium constituted of countries from endemic areas (India, Peru, Tunisia, Spain and France) and embracing multi-disciplinary approaches has been set-up. Based on successful results on VL dogs, the best VL animal model to date, RAPSODI will propose a second generation human-compatible vaccine candidate and confirm its activity in pre-clinical studies. As the chosen antigen is common to most, if not all, Leishmania species, an ambitious universal immunoprotective response is being sought. RAPSODI will also address the question of population selection in order to ascertain relevant and meaningful clinical trials and vaccination campaigns. Indeed, resistant individuals, when involved in either vaccinated or placebo groups, represent important bias to the analysis of the results. RAPSODI will investigate further the parasitological, immunological and genetic features of such clinical status, and will subsequently apply the generated knowledge to the development of assays and field tests, which represent stand-alone results. The package (vaccine candidate + diagnostic/prognostic tools) proposed by RAPSODI represents a global solution, and as such is believed to have a real impact on the worldwide leishmaniasis problem.

Keywords: leishmaniasis,leishmania,vaccine,pre-clinical trials,vaccine candidate,vaccination,diagnosis,efficacy follow-up,resistance features.
Development of cardiomyocyte replacement strategy for the clinic (CARDIOCELL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,France,Germany,United Kingdom,Germany,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-05-01
End date: 2012-10-31
Duration (months): 42.0
Total project cost (EUR): 3586220.12
EU funding (EUR): 2700000.0
Participants: 7
Project status: CLOSED

Heart failure as a result of myocardial infarction or ischemic heart disease is a major health problem in Europe. Currently the only long term solution is heart transplantation but one in three patients die while awaiting a match. Transplantation of an alternative cell source is extremely attractive but has so far met with very little success. Thus, skeletal muscle myoblasts led to recurrent arrhythmias with potential lethal effects, whereas the hopes for bone marrow transplantation have been largely dashed by the low efficiency and lack of evidence for trans-differentiation. In this project, we plan to mount a concerted and integrated effort to identify cells within the adult and developing heart with repair potential. We will characterise the cells to enhance their purification from, or stimulation within, foetal or adult tissue. In addition, we will determine how they are made during embryonic development to further improve the chances of manipulating their activity in vivo and also to increase the efficiency of their generation from embryonic stem cells. Cardiomyocytes generated in any of these ways will be genetically profiled and physiologically tested, both in vitro and after transplantation, to ensure their proper functional integration into the resident myocardium. In preparation for eventual transplantation into patients, we will explore biomatrices as supports for these cells and also approaches to suppressing the inflammatory response to increase the chances of graft survival.

Keywords: cardiomyocyte stem cell cell therapy
Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices (MASTERSWITCH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Greece,United Kingdom,France,Germany,Austria,United Kingdom,Sweden,Switzerland,Germany,United Kingdom,Spain,United Kingdom,Sweden,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-12-01
End date: 2013-11-30
Duration (months): 60.0
Total project cost (EUR): 14805808.18
EU funding (EUR): 11235980.0
Participants: 20
Project status: CLOSED

Objective: To delineate the biological and molecular pathways that initiate and drive chronic inflammatory disease and to transform the knowledge obtained into the development of novel anti-inflammatory interventions. Focus will be given to Rheumatoid Arthritis (RA) since longitudinal data indicate that intensive treatment can prevent persistency and chronicity. State of the Art and beyond: The first generation of targeted therapies in chronic inflammatory disease used RA as prototype disease for clinical development. These therapies are now also used in other inflammatory disorders. Although treatments have been developed that are effective in a proportion of patients, they are aspecific, relatively toxic and do not mediate cure. Currently, it is unknown which molecular effects need to be induced and/or targeted to prevent induction or persistency of RA. However, this is within reach through a strong international consortium of world-leading European groups that cover both basic- and translational research. Work plan: The general strategy for the project is to enable parallel studies that are focussed on critical switch moments in the biological processes that drive chronicity of inflammation. As the consortium consists of a multidisciplinary team with basic- and clinical expertise, translational research will be conducted to delineate the molecular basis of dysregulated inflammation, the RA-specific autoimmune-response and organ specific pathobiology. The final aim is to develop novel- and specific anti-inflammatory therapies. Impact of the project: This project will (i) identify the molecular networks underlying chronic inflammation and thereby (ii) will define novel targets for drug-development as well as (iii) algorithms that will predict outcome of therapy. Moreover, within this project European SMEs will evaluate new interventions (iv) and this project will (v) offer a platform to rapidly develop ideas and patents into new therapies.

Keywords: inflammatory disease,molecular pathways,rheumatoid arthritis,chronic inflammation
The identification, characterisation and exploitation of novel Gram-negative drug targets. (AEROPATH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Germany,Sweden,United Kingdom,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2012-10-31
Duration (months): 48.0
Total project cost (EUR): 6049979.0
EU funding (EUR): 4591463.0
Participants: 5
Project status: CLOSED

An ambitious long-term programme of multidisciplinary research with two closely linked objectives is proposed to support antimicrobial drug development. Firstly, to advance understanding, at the molecular level, of fundamental and important aspects of the biology of Gram-negative bacteria using the important pathogen model Pseudomonas aeruginosa. Secondly, and most important, to exploit our discoveries and develop ligands and inhibitors (hit and lead compounds) with the potential to underpin the discovery of improved therapies for Gram-negative infections. The research covers five distinct areas, or work packages. (WPI) The experimental validation and therefore identification of novel targets by gene knockout in P. aeruginosa. (WPII) Cloning, characterisation, biochemical and structural biology, of the novel targets. (WPIII) A directed, search for ligands/inhibitors, exploiting data from WPI and WPII, for these validated antimicrobial drug targets by virtual screening (VS) and assessment of druggabilty, high-throughput screening (HTS) of a carefully prioritised subset of targets. (WPIV) The characterisation of the interactions formed between the drug target and the ligand/inhibitor by biochemical and crystallographic study, computational modelling and then design and modelling to enhance binding properties. (WPV) The initial biological testing for efficacy against Gram-negative bacteria.

Keywords: pseudomonas drug targets structural biology antimicrobial crystallography screening
Nurse Forecasting: Human Resources Planning in Nursing (RN4CAST)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Belgium,Finland,Germany,Greece,Ireland,Netherlands,Spain,Sweden,Switzerland,United Kingdom,United States,Botswana,China,South Africa,Poland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2011-12-31
Duration (months): 36.0
Total project cost (EUR): 3826040.2
EU funding (EUR): 2999988.0
Participants: 15
Project status: CLOSED

Current human resources planning models in nursing are unreliable and ineffective as they consider volumes, but ignore effects on quality in patient care. The project RN4CAST aims innovative forecasting methods by addressing not only volumes, but quality of nursing staff as well as quality of patient care. RN4CAST is a consortium of 15 partners that will quantify in 11 European countries-Belgium, Finland, Germany, Greece, Ireland, Poland, Spain, Sweden, Switzerland, Netherlands, UK - important unmeasured factors in forecasting models including how features of hospital work environments and qualifications of the nurse workforce impact on nurse recruitment, retention, productivity and patient outcomes. Three partners outside Europe - China, South Africa, and Botswana- provide additional perspectives. Innovative elements of the project include unique measures of workplace dynamics and patient outcomes. Nurse workforce planning initiatives at national and European levels will be reviewed and newly collected data added to enhance accuracy for nurse workforce management. Data collection focuses on general hospitals, which employ the majority of nurses, account for the largest number of medical errors and comprise the largest share of national health expenditures. Each European partner will conduct a study of 20 to 50 hospitals depending on country size yielding information on more than 350 hospitals including surveys from over 50,000 nurses and outcomes of tens of thousands of patients. European partners were selected by geographic distribution, membership duration in the EU, research expertise and availability of patient discharge data. University of Pennsylvania, USA, will contribute specialized research expertise derived from previous international research. RN4CAST will be the largest nurse workforce study ever conducted in Europe, will add to accuracy of forecasting models and generate new approaches to more effective management of nursing resources in Europe.
Coordination of resources for conditional expression of mutated mouse alleles (CREATE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Germany,Greece,France,Germany,United Kingdom,United Kingdom,Canada,United States
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2011-10-31
Duration (months): 36.0
Total project cost (EUR): 1287738.07
EU funding (EUR): 1100000.0
Participants: 8
Project status: CLOSED

This proposal describes CREATE, an internationally based Coordination Action directly addressing a large scale data gathering activity for systematic conditional mouse mutagenesis. Advances in the sophisticated manipulation of the mouse genome has established the mouse as the premier organism for developing models of human disease. Internationally coordinated initiatives have established for the systematic generation of conditional mouse mutants on a large scale employing the Cre-lox binary system. Production of mutant mouse ES cell lines, each of which carries an altered or “floxed” allele of a single gene allows the creation of somatic mutations in defined genes. The full power of conditional mutants can only be exploited with the availability of well characterised mouse lines expressing Cre-recombinase in tissue, organ and cell type-specific patterns. Although several privately curated and locally held databases currently provide a limited catalog of existing Cre driver strains, these are not well integrated, and published data on Cre driver mice do not always capture critical details. CREATE will address these these combined shortcomings - inaccessibility to existing Cre driver strains, their incomplete characterisation, and an inadequate coverage of cell and tissue types in which they are active – which will soon constitute the major bottleneck for the future development of targeted conditional mutant models for the worldwide mouse mutagenesis initiative. Its main deliverables will be a well-annotated and integrated data resource of Cre driver strains, and coordination of the expansion of the resource, both necessary components of the international mouse mutagenesis effort. By enlisting major mouse stakeholders dedicated to collecting, integrating and curating, expanding and disseminating Cre driver mouse databases through a unified web portal, CREATE will provide the necessary structure for worldwide access to these critical resources.

Keywords: mouse,conditional mutagenesis,web resource
Developing efficient and responsive community based micro health insurance in India (CBHI INDIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Germany,India
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-07-01
End date: 2014-06-30
Duration (months): 60.0
Total project cost (EUR): 4010393.6
EU funding (EUR): 2999997.0
Participants: 6
Project status: CLOSED

Two generations of top-down decisions on health financing systems have produced very modest results for poor people, poor countries or indeed for the major donors/funders. In most developing countries, including India, the lion’s share of health spending is made out of pocket. Impoverishment, low access – especially for weaker segments of the population such as women and children – and thus bad health status are consequences. Health insurance has the potential to remedy or at least reduce the severe consequences of unforeseen health care expenditures. Recently, a growing number of community based health insurance (CBHI) schemes emerge in India and other developing countries. It is expected that CBHI can (i) help mobilizing additional resources for health financing, (ii) provide financial protection and (iii) increase access to health care and hence ultimately the health status of the rural population. Community based health insurance represent the highest hope for extension of insurance amongst the poor, drawing on experience of many western countries and Japan. However, in order to make use of the scarce resources available and build systems offering value to the poor, it is important to have a detailed and evidence based understanding on how to build an efficient and responsive CBHI-system. This proposed project sets out to close the knowledge gap on aspects important for the successful implementation of CBHI. It does so through a set of controlled field experiments through which CBHI is implemented in villages of three states of India. Rigorous longitudinal research documents the learning and makes it available for replication elsewhere. We apply quantitative research along with in depth qualitative research and spatial data. It is the project’s overall objective to: Use affordable, responsive and inclusive Community Based Health Insurance to increase: (i) Equitable access to healthcare and (ii) Financial protection.

Keywords: community based health insurance,micro health insurance,field experiment,access to care,cost-efficiency,financial protection,equity,women,india